Parathyroid Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Parathyroid cancer is an exceptionally rare endocrine malignancy, accounting for less than 1% of all cases of primary hyperparathyroidism — the most common setting in which parathyroid pathology is evaluated — and for approximately 1 case per million population annually. It arises from parathyroid chief cells and is almost universally functional, producing excess parathyroid hormone (PTH) that drives severe, potentially life-threatening hypercalcemia. Unlike benign parathyroid adenomas (the dominant cause of primary hyperparathyroidism), parathyroid cancer characteristically causes dramatically elevated calcium (often exceeding 13 mg/dL) and PTH levels that are typically more than three times the upper limit of normal. CDC73 (also called HRPT2) gene mutations encoding parafibromin are found in approximately 70% of sporadic parathyroid carcinomas and virtually all cases associated with hyperparathyroidism-jaw tumor syndrome. Metastasis most commonly occurs to regional lymph nodes, lungs, liver, and bone. The disease is often indolent, with recurrences developing over years, but ultimately is frequently incurable once distant metastases develop.

Inactivating mutations in the CDC73 gene (also designated HRPT2), which encodes the tumor suppressor protein parafibromin, are found in approximately 70% of sporadic parathyroid carcinomas and are the most common molecular event in this malignancy. Germline CDC73 mutations cause hyperparathyroidism-jaw tumor syndrome (HPT-JT) — an autosomal dominant condition characterized by parathyroid tumors (often carcinomas, occurring in approximately 15-20% of affected individuals), ossifying fibromas of the mandible and maxilla, uterine fibroids, and renal lesions. Multiple endocrine neoplasia type 1 (MEN1, menin gene mutations) is a rare additional associated syndrome. Sporadic parathyroid cancer has also been described after prior therapeutic radiation to the neck region. Secondary parathyroid carcinoma arising from longstanding tertiary hyperparathyroidism in chronic renal failure is recognized but uncommon. Most cases appear to arise de novo from random somatic molecular events.

The clinical presentation of parathyroid cancer is dominated by the consequences of severe hypercalcemia and massively elevated PTH acting on target organs over a prolonged period. Bone disease is prominent and severe: osteitis fibrosa cystica (subperiosteal bone resorption, brown tumors, pathological fractures), diffuse osteoporosis, and debilitating bone pain are characteristic. Renal manifestations include nephrolithiasis (kidney stones, often bilateral and recurrent), nephrocalcinosis, polyuria, polydipsia, and progressive chronic kidney disease. Severe hypercalcemia (often greater than 13 mg/dL) causes profound fatigue, lethargy, confusion or cognitive impairment, constipation, nausea, and vomiting. A palpable, often firm or hard neck mass (usually at or below the thyroid gland) is detectable in approximately 50% of patients with parathyroid cancer — a finding that should strongly raise suspicion for malignancy compared with benign adenoma, which is rarely palpable. Parathyroid crisis (calcium exceeding 15-16 mg/dL) is a life-threatening emergency requiring urgent IV hydration and bisphosphonate therapy.

Biochemical diagnosis rests on markedly elevated serum calcium (typically greater than 12-13 mg/dL) combined with markedly elevated intact PTH (typically more than three times the upper limit of normal), elevated serum alkaline phosphatase (reflecting bone turnover), elevated 24-hour urine calcium, and 25-OH-vitamin D deficiency. Cervical ultrasound is the initial anatomic imaging modality; 4D-CT or sestamibi SPECT/CT with or without SPECT provides functional localization. Histological diagnosis requires excisional surgical specimen — core needle biopsy is strongly discouraged due to the risk of seeding. Definitive histological criteria for malignancy include unequivocal capsular invasion (beyond the intact parathyroid capsule), vascular (venous) invasion, perineural invasion, or metastatic deposits. Parafibromin immunohistochemistry — loss of nuclear parafibromin expression — supports malignancy and correlates with CDC73 mutation. Germline CDC73 testing is strongly recommended for all patients with parathyroid carcinoma.

Complete en bloc surgical resection at initial surgery is the only potentially curative treatment and the single most important determinant of long-term outcome. The en bloc resection includes the parathyroid tumor with its intact capsule, the ipsilateral thyroid lobe, any adherent surrounding tissue, and pathologically enlarged regional lymph nodes. Frozen section of the specimen is unreliable for intraoperative diagnosis of malignancy because the histological features of cancer (capsular invasion, vascular invasion) cannot be definitively assessed on frozen section alone. Intraoperative PTH monitoring (the Miami criterion — greater than 50% PTH fall within 10 minutes of tumor removal) guides adequacy of biochemical cure. For inoperable or recurrent metastatic disease, hypercalcemia management is paramount: cinacalcet (calcimimetic, 30-180 mg daily) reduces PTH-mediated hypercalcemia; denosumab (anti-RANKL monoclonal antibody) manages skeletal complications; IV bisphosphonates and aggressive IV fluid hydration treat acute hypercalcemic crises. No proven systemic chemotherapy or targeted therapy regimen exists for progressive metastatic parathyroid carcinoma.

No established preventive measures exist for sporadic parathyroid carcinoma. For individuals with known germline CDC73 mutations or hyperparathyroidism-jaw tumor syndrome, regular biochemical monitoring — serum calcium, PTH, and alkaline phosphatase annually — enables detection of recurrence or de novo parathyroid pathology. First-degree relatives of patients with germline CDC73 mutations should undergo genetic testing and, if mutation-positive, regular biochemical surveillance starting in early adulthood. All patients with a CDC73-associated syndrome should also undergo periodic renal imaging and jaw X-rays to screen for associated lesions. Patients with prior neck irradiation who develop primary hyperparathyroidism should have a lower threshold for surgical exploration, with meticulous intraoperative assessment for malignant features. As parathyroid carcinoma has no known environmental risk factors beyond prior radiation, no behavioral modifications are established for primary prevention.

Any patient found to have serum calcium significantly above the upper limit of normal — particularly when asymptomatic hypercalcemia is first identified on routine blood work — requires evaluation by an endocrinologist to determine the cause. When PTH-dependent hypercalcemia is confirmed (elevated or inappropriately normal PTH with elevated calcium), surgical referral to an experienced parathyroid surgeon is appropriate. Parathyroid cancer should be specifically suspected when serum calcium is markedly elevated (above 12-13 mg/dL), PTH is more than twice to three times the normal upper limit, a palpable neck mass is present, and significant bone disease or bilateral kidney stones are present. Any patient with established hyperparathyroidism who develops a palpable neck mass or rapid worsening of hypercalcemia requires urgent evaluation. Genetic counseling should be offered to all patients with parathyroid carcinoma to assess for CDC73 germline mutation and family implications.

Complete en bloc resection at initial surgery: 5-year survival approximately 85%. Recurrence occurs in approximately 50% of patients over time, often biochemically (rising calcium/PTH) years after initial surgery. Re-resection of locoregional disease can achieve further remissions. Metastatic disease is incurable but may be managed for years with hypercalcemia control. Lifelong biochemical surveillance is essential. The prognosis for Parathyroid Cancer: Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.